Overview

Reduced drug use is a clinically meaningful target for treatment development, but few studies have evaluated the positive impacts produced by this behavioral change, preventing adoption of this endpoint in clinical trials. The proposed research will fill that critical knowledge gap by demonstrating the biopsychosocial benefits of reduced methamphetamine use. These data will be used to change current accepted methamphetamine treatment endpoints and accelerate identification of therapies for methamphetamine use disorder.

Eligibility

Inclusion Criteria:

• be age 18 years or older;
• self-report methamphetamine use in the week prior to screening;
• provide a methamphetamine-positive urine sample at screening;
• meet DSM-5 criteria for moderate-severe Methamphetamine Use Disorder (MUD);
• be seeking treatment for their methamphetamine use
• be able and willing to commit to the 12-week intervention, as well as the 12-week post-intervention follow-up
• Individuals who meet these criteria and are stably maintained on buprenorphine or methadone for Opioid Use Disorder (OUD) will also be eligible to participate.

Exclusion Criteria:

• current or past medical or psychiatric illness (e.g., physical dependence on any drug other than buprenorphine requiring medically managed detoxification, unstable angina, uncontrolled cardiac arrhythmia, aortic stenosis, self-reported compromised immune function, severe diagnosis for a SUD other than MUD or treated OUD) that would interfere with study participation in the opinion of the study physicians
• poor venous access precluding blood draws